

Edgar Filing: PRO PHARMACEUTICALS INC - Form 8-K

PRO PHARMACEUTICALS INC  
Form 8-K  
March 23, 2005

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 OR 15(d) of  
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 22, 2005

PRO-PHARMACEUTICALS, INC.

-----  
(Exact name of registrant as specified in its charter)

|   |                                      |   |
|---|--------------------------------------|---|
| Nevada  | 000-32877                            | 04-3562325                                    |
| -----<br>(State or other jurisdiction<br>of incorporation)                          | -----<br>(Commission<br>File Number) | -----<br>(IRS Employer<br>Identification No.) |
| 189 Wells Avenue, Newton, Massachusetts<br>(Address of principal executive offices) |                                      | 02459<br>(Zip Code)                           |

Registrant's telephone number, including area code: (617) 559-0033

-----  
Not Applicable  
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

On March 22, 2005, we issued a news release announcing results of experiments that reveal when DAVANAT(R) is co-administrated with 5-FU and the anti-Vascular

Edgar Filing: PRO PHARMACEUTICALS INC - Form 8-K

Endothelial Growth Factor (VEGF) drug, Avastin(TM), to mice implanted with human colon tumor (COLO 205), DAVANAT(R) significantly improves anti-tumor activities of the combination and doubles the tumor shrinkage rate. The news release is furnished as Exhibit 99.1 hereto.

Item 9.01 Financial Statements and Exhibits.

(c) Exhibits

99.1 News release of Pro-Pharmaceuticals, Inc. dated March 22, 2005.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

PRO-PHARMACEUTICALS, INC.

By: /s/ David Platt

-----  
David Platt  
President and Chief Executive Officer

Date: March 23, 2005